Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





SARS-CoV-2 Variants Could Help in Predicting COVID-19 Patient Outcomes

By HospiMedica International staff writers
Posted on 04 May 2021
Scientists who used genomic sequencing to track SARS-CoV-2 as it mutated have found that initial strains and subgroups of virus strains (called clades) were associated with higher mortality while newer variants were associated with lower hospitalizations and deaths.

These findings by a multidisciplinary team of scientists at Case Western Reserve University (Cleveland, OH) and Cleveland Clinic (Cleveland, OH) could also help guide future studies to analyze how the newer variants impact patient outcomes as the virus continues to evolve.

To better understand how the earlier mutations and clades altered clinical outcomes, the team of researchers analyzed the RNA sequences of data from 302 patients with COVID-19 during the first wave of the pandemic in Northeast Ohio. More...
These clinical samples were obtained from Cleveland Clinic’s COVID-19 registry, a collection of data from nearly 50,000 patients who had been tested for the disease. By sequencing each specimen against the initial strain of the virus discovered in Wuhan, the research team identified 488 unique mutations, correlating with six virus strains (clades Wuhan, S, L, V, G, GH).

Results revealed that during the initial six weeks of the pandemic in Cleveland, the early virus strains were well established and contributed to higher incidents of death from the disease. However, within weeks these early virus strains were outpaced by more transmissible strains that were associated with lower hospitalizations and increased patient survival even when hospitalized. The greatest diversity of COVID-19 strains occurred in the first weeks before community strategies to limit viral spread were established. It is likely that state and federal responses may have prevented continued introduction of new variants from outside the community, and thereby decreased overall mortality.

“This study offers a detailed description of how the different COVID-19 clades evolved and competed once they were brought to Cleveland,” said Brian Rubin, chair of Cleveland Clinic’s Robert J. Tomsich Pathology and Laboratory Medicine Institute. “The linkage of viral clades to outcomes is quite important and highlights the importance of viral genome sequencing to gain a deeper understanding of new diseases.”

“These findings offer greater insight into how COVID-19 infections significantly outpaced the rates of COVID-19 hospitalizations and deaths as the pandemic progressed,” said Frank Esper, a pediatric infectious disease physician at Cleveland Clinic Children’s who led the research collaborative. “The research also helps to validate how viral clades can play an important role in predicting patient outcomes.”

Related Links:
Case Western Reserve University
Cleveland Clinic



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.